10-Q quarterly report · filed Nov 5, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 10-Q Quarterly Report

Short answer

Amphastar Pharmaceuticals, Inc. (AMPH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $208M (up 8.2% year over year) with net income of $38M.

Q3 2026 key financials · XBRL

Revenue
$208M
+8.2% YoY · +12.9% QoQ
Net income
$38M
+117.7% YoY · +24.4% QoQ
Operating margin
24.5%
Gross margin
48.0%
EPS (diluted)
$0.86
+132.4% YoY · +28.4% QoQ

Source: XBRL data from the Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 10-Q on SEC EDGAR. USD.

Amphastar Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $207.6M, up from $191.8M YoY, driven by BAQSIMI, Primatene MIST, and ipratropium bromide
  • Gross profit $99.6M, margin 48.0% vs 51.4% YoY
  • Best performer: BAQSIMI revenue $58.8M, up $5.2M; worst: glucagon $8.6M, down $5.0M, or 37%
  • Nine-month operating cash flow $142.5M vs $123.3M; $100.0M BAQSIMI milestone payment and $75.1M treasury-stock purchases
  • Outlook: glucagon sales expected to decline; IMS remediation may slow production and increase manufacturing expenses

Risk Factors

  • IMS FDA warning letter, July 2, 2026, cited cGMP violations and triggered remediation efforts
  • IMS product-release backlog approximately $12.5 million as of September 30, 2026
  • IMS voluntarily suspended one product’s manufacture to prioritize products at shortage risk
  • Insider-pledged shares expose stock price to forced-sale risk across 5.7 million pledged shares
  • Credit lines totaled up to $57.0 million, including UBS’s unilateral call rights and lender acceleration rights

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Amphastar Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.